141 related articles for article (PubMed ID: 30545986)
1. An Oncologist's Letter to Santa: Bring Me Drugs!
Tempero M
J Natl Compr Canc Netw; 2018 Dec; 16(12):1411. PubMed ID: 30545986
[No Abstract] [Full Text] [Related]
2. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
Kantarjian H; Mathisen MS; Lipton JH
JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
[No Abstract] [Full Text] [Related]
3. Medicine. Shortages of cancer drugs put patients, trials at risk.
Kaiser J
Science; 2011 Apr; 332(6029):523. PubMed ID: 21527686
[No Abstract] [Full Text] [Related]
4. The shortage of essential chemotherapy drugs in the United States.
Gatesman ML; Smith TJ
N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
[No Abstract] [Full Text] [Related]
5. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
6. Indian patients go to court over cancer drug.
Murdur G
BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889
[No Abstract] [Full Text] [Related]
7. Running short.
Mettner J
Minn Med; 2011 Oct; 94(10):8-10. PubMed ID: 23256277
[No Abstract] [Full Text] [Related]
8. An Oncologist's Letter to Santa.
Tempero M
J Natl Compr Canc Netw; 2016 Dec; 14(12):1491. PubMed ID: 27956532
[No Abstract] [Full Text] [Related]
9. Drug shortages--a critical challenge for the generic-drug market.
Chabner BA
N Engl J Med; 2011 Dec; 365(23):2147-9. PubMed ID: 22040167
[No Abstract] [Full Text] [Related]
10. Five drugs facing key patent expirations and potential generic entry from April to May 2020.
Friedman Y
Pharm Pat Anal; 2020 May; 9(2):41-43. PubMed ID: 32314664
[TBL] [Abstract][Full Text] [Related]
11. Not everyone is perfct: about off-patent drugs.
Ann Oncol; 2001 Jun; 12(6):728. PubMed ID: 11484945
[No Abstract] [Full Text] [Related]
12. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
13. Eliminate cost-plus reimbursement for drugs.
Conti RM
Clin Adv Hematol Oncol; 2014 Jan; 12(1):66. PubMed ID: 25129910
[No Abstract] [Full Text] [Related]
14. Ending the shortage of generic oncology drugs.
Eagle D
Oncology (Williston Park); 2012 Jan; 26(1):17, 89. PubMed ID: 22393791
[No Abstract] [Full Text] [Related]
15. Roche's decision to drop Herceptin patent in India opens way for generics.
Limb M
BMJ; 2013 Aug; 347():f5197. PubMed ID: 23959293
[No Abstract] [Full Text] [Related]
16. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
17. [What drug companies actually do].
Tonby K
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1806. PubMed ID: 17599137
[No Abstract] [Full Text] [Related]
18. Drugs are scarce as mix of programs aims to ease access.
Brower V
J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
[No Abstract] [Full Text] [Related]
19. Countering delays in introduction of generic drugs.
Lancet; 2002 Jan; 359(9302):181. PubMed ID: 11812545
[No Abstract] [Full Text] [Related]
20. Is India ready to lead the battle for fair access to medicines?
Lancet Oncology
Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
